The presence of prostate-specific antigen checked more than 1 year before diagnostic biopsy is an independent prognostic factor in patients undergoing radical prostatectomy

• Published in: Investigative and clinical urology Vol. 62; no. 4; pp. 438 - 446
• Main Authors: Park, Sung Gon, Shim, Kang Hee, Choo, Seol Ho, Kim, Se Joong, Kim, Sun Il
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Urological Association 01.07.2021; Korean Urological Association; 대한비뇨의학회
• Subjects: Aged; Biopsy, Needle; cancer screening; Humans; Male; Margins of Excision; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local - blood; Neoplasm Staging; Original; Prognosis; Prostate - pathology; prostate cancer; prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; recurrence; retropubic prostatectomy; Retrospective Studies; Time Factors; Tumor Burden; 비뇨기과학; Recurrence; Prostate-specific antigen; Prostate cancer; Retropubic prostatectomy; Cancer screening
• ISSN: 2466-0493; 2466-054X; 2466-054X
• DOI: 10.4111/icu.20200545

In large scale prospective studies, prostate-specific antigen (PSA)-screening not only decreased prostate cancer mortality, but also reduced biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP). We investigated the independent effect of the presence of PSA checked more than 1 year before diagnostic biopsy on the prognosis of patients undergoing RP in a real world setting without PSA-screening. We reviewed the database of patients undergoing RP at Ajou University Hospital from March 1999 to May 2018. Clinicopathological features assessed were age, presence of lower urinary tract symptoms at presentation, presence of PSA checked over 1 year before biopsy, presence of PSA checked within 4 to 1 years of biopsy, last pre-biopsy PSA (pPSA), biopsy grade group (bGG), cT, cN, percentage of positive biopsy cores (PPBC), pathological GG (pGG), pT, pN, surgical margin, and index tumor diameter. The primary endpoint was BCR-free survival (BCRFS). Of 598 patients enrolled, 211 experienced BCR at the mean follow-up of 64±37 months. The 5-year and 10-year BCRFS were 62.8% and 53.9%, respectively. In multivariate analyses including clinical variables only, pPSA, bGG, cT, PPBC, and PSA within 4 to 1 years of biopsy independently affected BCRFS. In multivariate analyses including pathological variables only, pPSA, pGG, pT, pN, PSA checked over 1 year before biopsy and PSA checked within 4 to 1 years of biopsy independently affected BCRFS. Patients who has checked PSA at least once beyond 1 year before diagnosis of prostate cancer show better BCRFS regardless of other factors.